RxDoctor Payments Data

Shimul Sahai, MD

Pain Medicine · Chandler, AZNPI 1376761577

Payments from drug & device makers

$1,380in general payments, 2019–2025

Across 71 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$289
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$145
  • Protega Pharmaceutials Inc$121
  • Collegium Pharmaceutical, Inc.$90
  • Biodelivery Sciences International, Inc.$87
  • Novartis$60
  • plus $589 from 23 others

What the payments were for

  • Food & beverage$1,35998%
  • Education$212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,380 in reported general payments places this provider in the 25th percentile of 180 pain medicine providers in Arizona.

See all pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$77,652
Medicare patients
157
Services billed
1,910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide12$62,913
Fentanyl19$14,486
BotoxOnabotulinumtoxina11$11,424
MovantikNaloxegol Oxalate23$11,339
Lidocaine48$6,352
Pregabalin101$5,502
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen168$3,790
Oxycodone Hcl166$3,656
Celecoxib36$2,592
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen57$1,657
Gabapentin113$1,427
Tizanidine Hcl84$1,053
Morphine Sulfate ErMorphine Sulfate33$964
Methocarbamol49$850
Baclofen48$693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$145$62,91312 claims
AbbVieBotox$29$11,42411 claims
Redhill Biopharma Inc.Movantik$25$11,33923 claims
Hikma Pharmaceuticals USAMorphine Sulfate$21$53724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 180 pain medicine providers in Arizona.

Other pain medicine in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →